Prémio BIAL de Medicina Clínica 2020 distinguishes work on familial amyloid polyneuropathy, cancer and COVID-19
BIAL FOUNDATION DISTINGUISHES WORK ON FAMILIAL AMYLOID POLYNEUROPATHY WITH 100 THOUSAND EUROS PRIZE The “Prémio BIAL de Medicina Clínica 2020” has distinguished a team coordinated by Teresa Coelho, Director of the Neurophysiology Department at the Academic Medical Centre of Porto, for the work “A Paramiloidose em Portugal e no mundo: de doença fatal a doença crónica com qualidade de vida preservada” (Paramyloidosis in Portugal and the world: from fatal disease to chronic disease with preserved quality of life).
World Parkinson’s Day
To commemorate World Parkinson’s Day, BIAL is launching a new feature on their Keep It ON website, a Training Area. This new area has been created with Parkinson’s patients in mind, so they can keep active and healthy during these challenging times. The content for this Training Area has been developed in partnership with European Parkinson's Disease Association (EPDA), as well as experts in nutrition, voice and cognition. The resources produced will be published the coming months on the Keep It ON website, where they can be viewed, free of charge, in your preferred language (portuguese, spanish, german or english). For the launch of this initiative, we will publish content related to “exercise” and “nutrition”, followed by “voice” and “cognition” resources. We believe that a specialized version of these themes, one that encompasses the challenges posed by Parkinson’s, is a step forward, towards the empowerment of patients. For more information on this international initiative and content please visit Keep It ON.
BIAL invests 330 thousand euros in solar energy
BIAL completed the installation of 1244 solar panels of 410W with an installed capacity of 510kWp, equivalent to supply an average of 200 homes for a year. The panels cover an area of approximately 2500 m2 on the roof of the company's headquarters buildings. The pharmaceutical company invested 330 thousand euros in the installation of a solar photovoltaic system that will allow the annual production of approximately 746 741kWh and a reduction of 351 tons in CO2 emissions per year (approximately equivalent to the capture of CO2 by 2176 trees). José Redondo, General Manager of the Financial and Industrial Area, emphasizes that “this project reflects the company’s commitment, assumed several years ago, and the responsibility of BIAL to continue to innovate in the incorporation of sustainability in the management of the business and its operations, as well as the ambition to protect the environment and contribute to a more sustainable economy.” BIAL is one of the companies that joined, in 2019, the Letter of Commitment “Business Ambition for 1.5 ºC - Our Only Future”, launched by the United Nations Global Compact, that encourages companies, worldwide, to create concrete measures to fight against climate change, setting goals and objectives to reduce emissions of greenhouse gas effect, reaching zero net emissions by 2050 and limit global warming to 1.5 °C by 2030. In 2001, BIAL was the first pharmaceutical and healthcare company in Portugal to obtain the Environmental Management System Certification.
International Epilepsy Day
The 8th of February marks the International Epilepsy Day, a day of enormous relevance for the community of patients and their families, who daily live with this pathology. Currently, epilepsy affects more than 50 million people worldwide making it a high incidence condition. More than 10 years ago, BIAL began a journey in this therapeutic area, providing an innovative solution resulting from an important research and development effort, thus taking the first step in the commitment to epilepsy. On this date, we want to reinforce our commitment and take a big step in raising awareness of this condition. One Big Step for Epilepsy is the motto of a campaign that includes a set of communications on digital and corporate channels and a page that will mirror several relevant facts for people living with epilepsy, their families and the general public: www.onebigstepforepilepsy.com. Not only does BIAL want to take this huge step towards epilepsy, but it calls for everyone to join in this action and help to demystify and promote global awareness of epilepsy. How? Symbolically joining your steps to ours. Just add all your steps on this day, counted through your mobile phones, fitness bands or smartwatches, and insert them on the page www.onebigstepforepilepsy.com. Each step is a contribution. Our contribution for Epilepsy.
Horta-Osório replaces Luís Portela as Chairman of BIAL
Porto, 22nd January 2021 - António Horta-Osório will be the new Chairman of the pharmaceutical company BIAL from April onwards, after leaving the position of Executive President of Lloyds bank. He will replace Luís Portela, the main shareholder of the company and its president for the past 42 years. António Portela will continue to lead BIAL’s Executive Committee.
BIAL obtains the renewal of the Certificates of its Management Systems of Quality, Environment and Occupational Health and Safety
Certificates of Management Systems of Quality, Environment and Occupational Health and Safety, implemented in accordance with ISO 9001 / ISO 14001 / ISO 45001 standards, respectively
BIAL Goes Global with New US Research Center and Acquisition of Promising Parkinson's Disease Programs
BIAL Biotech to be based in Cambridge, Massachusetts and will be a Research Center of Excellence dedicated to genetically-defined Parkinson’s disease LTI-291 clinical program and other research programs in Parkinson's disease acquired from Lysosomal Therapeutics, Inc R&D team led by Peter Lansbury, professor of neurology at Harvard Medical School Investment may add up to 130 million dollars depending on the accomplishment of downstream development, and several regulatory and commercial milestones
Opicapone approved in Japan
BIAL announced today that Opicapone tablets 25 mg received a manufacturing and marketing approval in Japan for the improvement of the end-of-dose motor fluctuations (wearing-off phenomenon) in Parkinson's disease in combination with levodopa-carbidopa or levodopa–benserazide hydrochloride.
FDA approves Opicapone
BIAL announced today that the U.S Food and Drug Administration (FDA) has approved Opicapone as an add-on treatment to levodopa/carbidopa in patients with Parkinson’s disease experiencing “off” episodes. “We are very pleased to achieve this major regulatory milestone for Opicapone, which offers patients living with Parkinson´s disease an effective, once-daily adjunctive treatment option to the gold standard levodopa/dopa-decarboxylase inhibitors preparations. This approval is a landmark in BIAL’s ongoing commitment to the quality of life of Parkinson’s patients and their caregivers. We look forward to working with our partner in the U.S., Neurocrine Biosciences, to make this therapy available to patients.” said António Portela, CEO of BIAL. In February 2017, BIAL and Neurocrine Biosciences entered into an exclusive licensing agreement for the development and commercialization of Opicapone in the U.S. and Canada. The commercial launch of Opicapone in the U.S.is expected to occur later in 2020. The FDA approval of Opicapone is supported by data from 38 clinical studies, including two multinational Phase III clinical studies (BIPARK-1 and BIPARK-2). In BIPARK-1, a randomized, double-blind placebo- and active-controlled study, approximately 600 patients with Parkinson’s disease and end-of-dose motor fluctuations received once-daily doses of Opicapone (5 mg, 25 mg, or 50 mg), placebo or 200 mg of the COMT (catechol-O-methyltransferase) inhibitor entacapone for 14 to 15 weeks as adjunct to levodopa therapy. In BIPARK-2, which followed a similar study design, approximately 400 patients received once-daily doses of Opicapone (25 mg or 50 mg) or placebo
BIAL takes responsibility for its website contents. By clicking “continue” below, you will be taken to an external website, beyond our responsibility.